<DOC>
	<DOCNO>NCT00352547</DOCNO>
	<brief_summary>This study evaluate effect certain gene ( MDR-1 , CYP3A4 , CYP3A5 ) metabolism drug sirolimus , immune-suppressing drug give transplant recipient prevent organ rejection . Individual difference metabolism excretion sirolimus affect patient 's response treatment . Patients undergone kidney transplantation National Institute Diabetes Digestive Kidney Diseases ( NIDDK ) Transplant Branch receive sirolimus treatment enrol study . DNA ( genetic material ) extract blood sample collect transplant recipient determine MDR-1 , CYP3A4 , CYP3A5 genotypes . Patient demographic information data sirolimus metabolism excretion collect medical information system , NIDDK transplant database , patient ' medical record . The data compare among patient different genotype ( genetic constitution individual ) haplotype ( set gene code different protein inherit unit ) determine effect gene variation sirolimus metabolism . Information study may apply develop well dose strategy , thus , treatment outcome transplant patient receive sirolimus .</brief_summary>
	<brief_title>Influence Genes Sirolimus Metabolism Patients With Kidney Transplantation</brief_title>
	<detailed_description>The immunosuppressant sirolimus substrate drug efflux pump p-glycoprotein ( Pgp ) hepatic intestinal drug metabolize enzyme cytochrome P450 3A4/5 ( CYP3A4/5 ) . Single nucleotide polymorphism ( SNPs ) multi-drug resistance ( MDR ) -1 gene encodes Pgp , CYP3A4 , CYP3A5 gene show associate altered metabolism various drug include immunosuppressant cyclosporine tacrolimus . This protocol evaluate effect MDR-1 , CYP3A4 , CYP3A5 gentotypes/haplotypes pharmacokinetics pharmacodynamics sirolimus patient renal transplantation . All patient kidney transplantation National Institute Diabetes Digestive Kidney Diseases ( NIDDK ) Transplant Branch , participate one NIDDK therapeutic protocol , receive sirolimus enrol study . Selected MDR-1 , CYP3A4 , CYP3A5 SNPs determine polymerase chain reaction base method use exist patient blood sample . Demographic , pharmacokinetic , pharmacodynamic data collect medical information system , NIDDK transplant database , medical record patient . Population pharmacokinetic parameter pharmacodynamic measurement compare among patient different MDR-1 , CYP3A4 , CYP3A5 genotypes/haplotypes . Results study help understand effect pharmacogenetics sirolimus pharmacokinetics pharmacodynamics , provide information rationalize sirolimus dose patient renal transplantation .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients meet follow criterion include study : Underwent kidney transplantation NIDDK Transplant Branch ; Participated one NIDDK therapeutic protocol , Have receive switched sirolimus EXCLUSION CRITERIA : Patients clearly document noncompliance medication include sirolimus exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2, 2013</verification_date>
	<keyword>Immunosuppresant</keyword>
	<keyword>Genetic Polymorphism</keyword>
	<keyword>Drug Metabolism</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Rapamycin</keyword>
</DOC>